Evogene Ltd Earnings: Miss on EPS and Revenue

Evogene Ltd (EVGN) reported disappointing first-quarter results on May 20, 2026, missing analyst expectations on both earnings per share and revenue. The biotechnology company posted a loss of $0.60 per share, significantly worse than the estimated loss of $0.28 per share.

The EPS miss represented a negative surprise of 117.86%, with actual losses more than doubling analyst projections. The $0.60 per share loss compared unfavorably to the consensus estimate, highlighting operational challenges during the quarter.

Revenue came in at $330,000, falling short of the $357,000 analyst estimate by 7.56%. The revenue shortfall of $27,000 contributed to the company’s wider-than-expected losses for the reporting period.

The combined EPS and revenue misses suggest Evogene faced headwinds in executing its business strategy during the quarter. The 117.86% EPS surprise magnitude indicates the extent to which actual performance diverged from Wall Street expectations.

This article is for informational purposes only and does not constitute investment advice. Past performance does not guarantee future results.